Management of hemophilia in patients with inhibitors: the perspective from developing countries

Area of Science:

• Hematology
• Immunology
• Global Health

Background:

• Limited data exist on inhibitor prevalence in people with hemophilia (PWH) in developing nations.
• A perception suggests lower inhibitor rates compared to developed countries, possibly due to delayed treatment with plasma-derived clotting factors.
• Genetic and environmental factors require further investigation.

Purpose of the Study:

• To highlight the limited data on inhibitors in PWH in developing countries.
• To emphasize the need for improved laboratory infrastructure and quality control for inhibitor testing.
• To discuss individualized management strategies considering socioeconomic diversity and resource availability.

Main Methods:

• Review of existing literature and data on inhibitor prevalence in PWH.
• Analysis of treatment practices and their potential impact on inhibitor development.
• Discussion of management options, including bypassing agents and immune tolerance induction.

Main Results:

• Inhibitor prevalence data in developing countries are scarce, with estimates ranging from 7-19%.
• Treatment initiation after two years of age with plasma-derived concentrates may influence inhibitor rates.
• Management approaches must be individualized due to significant socioeconomic variations.

Conclusions:

• Developing countries require enhanced laboratory infrastructure and quality control for inhibitor diagnostics.
• Judicious use of bypassing agents and systematic patient screening can improve care for PWH with inhibitors.
• Further research on immune tolerance induction with low-dose regimens is warranted.